ArticleCureus2026
Association Between COVID-19 Vaccine Doses and Neurosensory Symptoms Among COVID-19-Positive Patients: A Retrospective Cross-Sectional Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAgeusia and anosmia are common manifestations of COVID-19. This study examined whether their frequency among infected patients was associated with the recorded number of Pfizer-BioNTech vaccine doses; it was not designed to estimate causality or vaccine effectiveness.
methodsWe conducted a retrospective cross-sectional analysis of 5,348 COVID-19-positive patients over five years of age followed by the San Miguelito Health Region, Panama, from July 7, 2021, through November 2, 2022. Unvaccinated patients and vaccinated patients whose recorded doses were exclusively Pfizer-BioNTech were included. Separate logistic regression models estimated associations between vaccine dose category (zero, one, two, or three to four doses) and self-reported ageusia and anosmia, with two doses as the reference. A post hoc sensitivity analysis additionally adjusted for swab month.
resultsAgeusia was reported by 507 patients (9.48%), and anosmia by 584 patients (10.92%). In the primary adjusted models, compared with two doses, adjusted odds ratios (aORs) for zero, one, and three to four doses were 1.87 (95% confidence interval (CI) 1.48-2.38), 2.68 (95% CI 1.99-3.60), and 0.26 (95% CI 0.18-0.36), respectively, for ageusia, and 1.82 (95% CI 1.46-2.27), 2.53 (95% CI 1.91-3.35), and 0.18 (95% CI 0.12-0.25), respectively, for anosmia. After categorical adjustment for swab month, all six dose-category estimates were attenuated, and none remained statistically significant.
conclusionsPrimary models identified strong associations between recorded vaccine dose category and self-reported ageusia and anosmia among infected patients, but these associations did not persist after adjustment for swab month. The results are compatible with substantial confounding by epidemic period and should not be interpreted as causal effects or estimates of vaccine effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.